Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Termination of PMCF study due to product discontinuation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objectives of this study are to confirm safety, performance and clinical benefits of the Anaverse™ Glenoid System and its instrumentation by analysis of standard scoring systems, radiographs and adverse event records.
The safety of the system will be assessed by monitoring the frequency and incidence of adverse events.
The performance and clinical benefits will be evaluated by assessment of the overall pain and functional performance, survival, and radiographic parameters of all enrolled study subjects.
The primary endpoint is defined by the survival of the implant system at 2 years which is based on removal or intended removal of the Anaverse™ Glenoid System baseplate and will be determined by using the Kaplan Meier method.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anaverse Shoulder System subjects | Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anaverse Shoulder System | Device | Reverse Shoulder Arthroplasty |
|
| Measure | Description | Time Frame |
|---|---|---|
| Survival of Implant System (Kaplan Meier) | The primary endpoint of this study is the survival of the implant (Reversed configuration) after 2 years, which is based on removal of the baseplate and will be determined using the Kaplan-Meier method. | 2 years post-op |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Constant Murley Shoulder Score (CM) | The Constant Murley (CM) Score comprises outcome measures of freedom from pain (15 points), full range of function (20 points), active range of movement (40 points), and full strength (25 points). The total score is an aggregate of the individual outcome measures. The minimum score is 0 points (worst outcome), the maximum score possible is 100 points (best outcome). | Pre-operative (baseline), 1 year, 2 years post-operative |
Inclusion Criteria:
Patient is 18-75 years of age, inclusive.
Patient is skeletally mature.
Patient is capable of understanding the doctor's explanations, following his instructions and is able to participate in the follow-up program.
Patient must have signed EC-approved informed consent.
Patient requires a primary reversed total shoulder arthroplasty or a conversion from anatomical to reversed to relieve pain and restore the joint function.
Patient has adequate quality and quantity of bone stock to support the prosthesis.
Patient meets at least one of the following indications:
Patient has significant shoulder disability due to gross and irreparable rotator cuff deficiency. A functional deltoid muscle is necessary to use the device.
Patient underwent reverse total shoulder reconstruction with the Anaverse Glenoid System before the date of site initiation.
Patient has demographic, pre-operative evaluation, operative report and device information available.
Specific inclusion criteria for Conversion from Anatomical to Reversed Configuration:
Exclusion criteria:
Specific exclusion criteria for Conversion from Anatomical to Reversed Configuration:
Not provided
Not provided
Not provided
Patients suffering from severe shoulder pain and disability indicated for implantation of the Anaverse™ Glenoid System in cases of total shoulder arthroplasty in reversed configuration. Patients who underwent total shoulder arthroplasty conversion from anatomical to reversed will be enrolled for subgroup analysis. Patients must meet all inclusion and none of the exclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hassan Achakri | Zimmer Biomet | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Balgrist University Hospital | Zurich | 8008 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Recruitment was terminated prematurely due to early termination of the study due to product rationalization for commercial reasons. 20 participants (21 cases) of the 30 planned cases were included.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Anaverse Shoulder System Subjects | Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed. Anaverse Shoulder System: Reverse Shoulder Arthroplasty |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Baseline Measures reported at participant level
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Anaverse Shoulder System Subjects | Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed. Anaverse Shoulder System: Reverse Shoulder Arthroplasty |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Survival of Implant System (Kaplan Meier) | The primary endpoint of this study is the survival of the implant (Reversed configuration) after 2 years, which is based on removal of the baseplate and will be determined using the Kaplan-Meier method. | Posted | Count of Units | Implants | 2 years post-op | Implants | Implants |
|
|
AEs were collected from the time of surgery until study completion (up to 2 years)
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Anaverse Shoulder System Subjects | Subjects implanted with the Anaverse Shoulder System in the reversed configuration and subjects who underwent total shoulder arthroplasty conversion from anatomical to reversed. Anaverse Shoulder System: Reverse Shoulder Arthroplasty |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Infection >6 weeks | Infections and infestations | Non-systematic Assessment | Revision surgery due to infection. Symptoms started 359 days after implantation. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Urinary disorder | Renal and urinary disorders | Non-systematic Assessment |
Limitations of this study are the low sample size of 21 cases as well as the short follow-up period of two years.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Carina Hafner | Zimmer Biomet | +41797073093 | carina.hafner@zimmerbiomet.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 28, 2022 | Mar 31, 2025 | Prot_SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D000070636 | Rotator Cuff Injuries |
| D020069 | Shoulder Pain |
| D007592 | Joint Diseases |
| ID | Term |
|---|---|
| D012421 | Rupture |
| D014947 | Wounds and Injuries |
| D000070599 | Shoulder Injuries |
| D013708 | Tendon Injuries |
Not provided
Not provided
Not provided
Not provided
Not provided
| Subjective Shoulder Value (SSV) | The Subjective Shoulder Value (SSV) is a single point, subjective estimate of a patient's condition. The patient is asked to rate the functionality of their operated shoulder on a scale of 0% - 100% of normal. | Pre-operative (baseline), 1 year, 2 years post-operative |
| Radiographic Parameters | Radiographic parameters: X-rays have been evaluated for radiolucency, osteolysis, atrophy, hypertrophy, osteophytes (glenoid), component migration (humeral implant subsidence / glenoid component migration), heterotopic ossification and scapular notching | Immediate post-op to 2 years post-operative |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race and Ethnicity Not Collected | Race and Ethnicity were not collected from any participant. | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| Height | Mean | Standard Deviation | cm |
|
| Weight | Mean | Standard Deviation | kg |
|
| Participants |
|
| Implants |
|
|
| Other Pre-specified | Constant Murley Shoulder Score (CM) | The Constant Murley (CM) Score comprises outcome measures of freedom from pain (15 points), full range of function (20 points), active range of movement (40 points), and full strength (25 points). The total score is an aggregate of the individual outcome measures. The minimum score is 0 points (worst outcome), the maximum score possible is 100 points (best outcome). |
| Posted | Mean | Standard Deviation | score on a scale | Pre-operative (baseline), 1 year, 2 years post-operative | Implants | Implants |
|
|
|
|
| Other Pre-specified | Subjective Shoulder Value (SSV) | The Subjective Shoulder Value (SSV) is a single point, subjective estimate of a patient's condition. The patient is asked to rate the functionality of their operated shoulder on a scale of 0% - 100% of normal. |
| Posted | Mean | Standard Deviation | percentage of normal | Pre-operative (baseline), 1 year, 2 years post-operative | Implants | Implants |
|
|
|
|
| Other Pre-specified | Radiographic Parameters | Radiographic parameters: X-rays have been evaluated for radiolucency, osteolysis, atrophy, hypertrophy, osteophytes (glenoid), component migration (humeral implant subsidence / glenoid component migration), heterotopic ossification and scapular notching | Posted | Count of Units | Implants | Immediate post-op to 2 years post-operative | Implants | Implants |
|
|
|
| 0 |
| 20 |
| 1 |
| 20 |
| 4 |
| 20 |
|
| Intraoperative humeral bone fissure | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Traumatic Injury (Not study shoulder) | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
| Instability - Luxation | Musculoskeletal and connective tissue disorders | Non-systematic Assessment |
|
Not provided
| D018771 |
| Arthralgia |
| D009140 | Musculoskeletal Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| 1 year |
|
|
| 2 years |
|
|
| 1 year |
|
|
| 2 years |
|
|
| No |
|
| Osteolysis - Humerus ≥ 2mm |
|
| Osteolysis - Glenoid |
|
| Atrophy |
|
| Hypertrophy |
|
| Osteophytes (Glenoid) |
|
| Component Migration (humeral implant subsidence / glenoid component migration) |
|
| Heterotopic Ossification - Grade 1 |
|
| Heterotopic Ossification - Grade 2 |
|
| Heterotopic Ossification - Grade 3-4 |
|
| Scapular Notching - Grade 1 |
|
| Scapular Notching - Grade 2-4 |
|